MedPath

Modified Xiaochaihu decoction combined with mirtazapine in the treatment of persistent depression: A pilot randomized controlled trial

Phase 1
Recruiting
Conditions
Persistent depressive disorder
Registration Number
ITMCTR2100005013
Lead Sponsor
The Sixth Medical Center of the General Hospital of the People's Liberation Army, Beijing, China
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Patients who meet the diagnostic criteria of PDD in DSM-5 and are accompanied by symptoms of chronic insomnia or pain;
2. SDS Self-Rating Scale (compiled by W.Zung in 1965, also known as Zung Self-Rating Depression Scale is one of the scales recommended by the U.S. Department of Education, Health and Welfare for psychopharmacology research. Because it is simple to use, it can reflect patients' subjective feelings of depression and its changes in treatment intuitively. At present, it has been widely used in outpatient rough screening, emotional state assessment, investigation, scientific research, etc. The total score >=41 points;
3. Aged 24 to 64 years;
4. Those who can correctly understand the content of the scale.

Exclusion Criteria

1. Patients who received other antidepressant treatment within 2 weeks of the beginning of this study;
2. Have a history of alcohol and drug dependence;
3. Pregnant women and lactating women;
4. Instable control of hypertension, diabetes and other chronic internal diseases;
5. abnormal liver and kidney function;
6. Patients with fever, pneumonia, trauma and other diseases.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Self-Rating Depression Scale;
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath